Blood pressure lowering retail terminal 20 billion fast running, amlodipine fierce competition
In recent years, the market for hypertension drugs has been growing under the demand for drugs from the huge population of hypertension in China. However, from 2015 to 2016, the overall growth rate of the hypertension drug market showed a downward trend due to the impact of bidding price reduction, medical insurance fee control and economic growth slowdown. As the situation changes, the growth rate of the hypertension drug market will bid farewell to the downturn.
At the AHA2017 Academic Annual Meeting, the American Heart Association and the American College of Cardiology jointly released the "New American Hypertension Guidelines", which was updated 14 years later. A new definition, a new depressurization threshold, a new depressurization target value and a new measurement "method" are proposed ". Hypertension is defined as blood pressure exceeding 130/80mmHg. For people> 65 years old, the new version of the guide is a big flip of the previous version of the guide. The study found that intensive antihypertensive therapy significantly reduced the risk of cardiovascular disease, but did not increase the risk of falls and orthostatic hypotension, which led to a reshuffle of the global hypertension treatment market.
Some domestic experts believe that there are differences in cardiovascular diseases among Eurasians. For example, coronary heart disease poses a greater threat to Caucasians, while Asians have a greater risk of stroke. Whether this standard can be adopted in China may still need to be evaluated by experts. However, a 2015 Lancet Medical Journal review has mentioned that blood pressure drops to 130/75mmHg can significantly reduce cardiovascular and cerebrovascular risks. The etiology of hypertension is complex, blood pressure is easy to fluctuate, and the choice of drug type and dose affects the effect of antihypertensive. Practice has proved that after many elderly hypertension in China have reached the standard through treatment, the risk of cardiovascular and cerebrovascular diseases is gradually declining.
High blood pressure challenges humans
According to a study in the Lancet, the number of people suffering from high blood pressure has increased to 1.13 billion, and 17 million people die from cardiovascular disease every year.
During the 45 years from 1958 to 2002, four hypertension surveys were completed in China. At present, the National Center for Cardiovascular Diseases is organizing the fifth national hypertension population survey. In June 2015, the Ministry of Health released that the prevalence of hypertension among people aged 18 and over in China was 25.2, and the number of patients reached 0.278 billion. Chronic diseases have become a major problem affecting the health of residents. The proportion of chronic diseases is higher in the elderly population, and the prevalence of hypertension in the elderly aged 65 and over is 52.4.
With the full coverage of the national medical security system and the attention of middle-aged and elderly people to health, the awareness rate, treatment rate and control rate of hypertension population have reached 46%, 41% and 14% respectively, which is a great progress compared with the beginning of this century, but still can not be taken lightly.
In recent years, the market for hypertension drugs has been growing under the demand for drugs from the huge population of hypertension in China. However, from 2015 to 2016, the overall growth rate of the hypertension drug market showed a downward trend due to the impact of bidding price reduction, medical insurance fee control and economic growth slowdown. But as the situation changes, the growth rate of the hypertension drug market will bid farewell to the downturn.
Domestic drugstore anti-hypertension retail market can reach nearly 200billion
In 2016, the retail market of domestic pharmacies was 337.7 billion yuan, up 9.18 from the previous year. The chemical drug market accounts for 49.52 percent of the total retail end drug market.
In 2016, the anti-hypertension retail terminal chemical drug market was 15.9 billion billion yuan, up 3.92 from the previous year. Under the background of big health and national policy guidance, it is expected that the anti-hypertension retail market in domestic pharmacies will reach nearly 20 billion market size in 2017.
In the antihypertensive retail terminal chemical drug market in 2016, there are 15 generic drugs in the TOP100 antihypertensive subcategory. Market share of 14.317 billion yuan. Among them, TOP10 varieties accounted for 70.22 of the domestic pharmacy retail hypertension market, and other varieties accounted for 29.78.
Data show that the domestic retail market of antihypertensive drug pharmacies shows a three-legged situation of nifedipine, amlodipine and levamlodipine, accounting for 40% of the retail market of antihypertensive drug pharmacies.
Amlodipine leads pharmacy retail
Amlodipine, a third-generation calcium antagonist, is a drug for the treatment of chronic stable angina pectoris and hypertension in coronary heart disease. It can reduce the risk of hospitalization due to angina pectoris and the risk of coronary artery reconstruction. The original research drug is Pfizer's Luo Huoxi. So far, CFDA has issued 98 approvals for amlodipine, and more than 70 companies are competing for this market. The competition is very fierce, and there are not a few well-known domestic brands.
According to the data of Mi Nai, the sales of amlodipine in domestic retail pharmacies reached 2.435 billion billion yuan in 2016, an increase of 7.22 over the previous year, accounting for nearly 1/3 of the total domestic amlodipine terminal market. Amlodipine TOP5 brand is Pfizer's Luo Huoxi, China Resources Seko Pharmaceutical's Yeshida, Yangzijiang Pharmaceutical's Shanghai Haini Company's Randy, Suzhou Dongrui Pharmaceutical's Annezhen, Kunming Saino Pharmaceutical's Xin Luoping. In domestic public hospitals and urban community terminals, the original research drugs are basically dominated by Huoxi, occupying more than 90% of the market, while retail pharmacies are evenly divided between the original research drugs and domestic drugs due to price factors. Under the factors of the increase in medical insurance pharmacies and the temporary inability to connect medical insurance outpatient clinics in different places, it is estimated that the amlodipine market in domestic retail pharmacies will reach a market size of 2.6 billion -3 billion yuan in 2017.
"Nitrate II" fierce competition
The second generation of nifedipine drugs refers to nifedipine controlled release tablets and nifedipine sustained release tablets. Nifedipine regular release tablets are the first generation of calcium antagonists. After the innovation of drug release technology, nifedipine regular release tablets have been the second generation of calcium antagonists and play an important role in clinical practice. In addition to lowering blood pressure, nifedipine has an effect on variant angina pectoris, unstable angina pectoris and chronic stable angina pectoris, so it is the advantage of nifedipine market competition.
According to data from the Intranet, the total sales of nifedipine in domestic retail pharmacies in 2016 was 2.585 billion yuan, an increase of 8.61 over the previous year. It is worth mentioning that nifedipine controlled-release tablets accounted for 56.02 per cent of the total for 1.448 billion yuan, an increase of 14.38 per cent over the previous year. Nifedipine sustained-release tablets were 1.137 billion yuan, with a growth rate of 2.06. In addition, the price of nifedipine regular release tablets is low, the dosage is gradually decreasing, and the proportion is less.
Nifedipine controlled release tablets are tablets with constant release rate and stable drug effect by using suitable skeleton materials, which are superior to sustained release tablets. The main brand sold in China is Bayer of Bayer of Germany, followed by Shanghai Hyundai's Xinran. The domestic nifedipine sustained-release preparations have tablets and capsules, with 27 holding registration numbers. The competition is fierce. Qingdao Huanghai Pharmaceutical's "Fuda", Yangzijiang Pharmaceutical Group's Jiangsu Pharmaceutical's "Huyou", Beijing Honglin Pharmaceutical's "Jiubaoping" and Guangdong Global Pharmaceutical's "Shengtong Ping" are among the best.
Levoamlodipine for board Luo Huoxi
Levamlodipine is the third generation calcium antagonist. At the end of the 20th century, it was successfully developed in China and listed. Levamlodipine is the L isomer of amlodipine. Compared with amlodipine, it has the characteristics of good curative effect, small adverse reactions and small dosage. Levamlodipine will easily cause side effects such as edema and no hypotensive effect of the "right-handed body" to split, retain the hypotensive effect of the left-handed body. At present, CFDA has issued 31 registration approvals, and 12 enterprises produce levamlodipine preparations.
According to the data of Mi Neiwang, the sales of levamlodipine in domestic retail pharmacies reached 1.569 billion yuan in 2016, an increase of 1.88 over the previous year. It is predicted that the retail pharmacy market will reach 1.837 billion yuan in 2017. In clinical practice, levamlodipine is especially suitable for elderly patients with coronary heart disease; levamlodipine has been used as a first-line drug for the treatment of hypertension, stable angina pectoris and variant angina pectoris.
Levamlodipine is one of the main varieties of calcium channel blockers, and many new processes and technologies of levamlodipine have been developed in China. According to reports, many domestic companies have disclosed the invention patent of the drug. Since the successful development and listing of levamlodipine in 1999, after continuous research and development by many companies, its crystal content and purity have been improved, impurities have been reduced, and the stability of drug quality has been guaranteed. It makes levoamlodipine a better drug than amlodipine, thus it is a strong growth variety in China's anti-hypertensive differential drug market.